EC Approves Additional Indication for Lynparza as Adjuvant Treatment in Breast Cancer

The European Commission has approved AstraZeneca and Merck’s Lynparza (olaparib) as an adjuvant treatment for BRCA-mutated HER2-negative high-risk early breast cancer.